Larsucosterol Shows Promising 90-Day Mortality Reduction in Phase 2b Alcohol-Associated Hepatitis Trial
• Phase 2b AHFIRM trial results published in NEJM Evidence demonstrate larsucosterol reduced 90-day mortality by up to 41% in alcohol-associated hepatitis patients compared to placebo.
• U.S. patient subgroup analysis revealed even more substantial mortality reductions of 57-58% with both 30mg and 90mg doses, showing strong statistical significance.
• The drug demonstrated a favorable safety profile with treatment-emergent adverse events comparable to placebo, marking a potential breakthrough for a condition with no FDA-approved therapies.
© Copyright 2025. All Rights Reserved by MedPath